

[CTP22] The Familial Intracranial Aneurysm (FIA) Study**Laura R Sauerbeck, RN MS. University of Cincinnati, Cincinnati, OH****Trial Name [REQUIRED]:** The Familial Intracranial Aneurysm Study**Trial Abbreviation:** FIA**Trial Registry Number or ID:** RO1 NS039512**Abstract (Include the following sections BACKGROUND, OBJECTIVE, DESIGN, POPULATION STUDIED (including sample size), INTERVENTION(S), OUTCOME MEASURE(S), ANALYSIS, TRIAL STATUS):****Background:** Subarachnoid hemorrhage (SAH) due to ruptured intracranial aneurysms (IAs) occurs in about 20,000 people per year in the United States. Unruptured IAs are estimated to be present in at least 1.0% of the population. Familial aggregation and population-based studies suggest that genetic factors play a role in IA and SAH. The goal of this National Institutes of Health (NIH) funded study, is to identify genes that increase the risk of developing IAs.**Subjects:** 475 families with multiple members diagnosed with IA will be enrolled. Eligible families include: 1) Families with at least 2 living affected siblings, 2) Families with at least 2 affected siblings, one is living and the other whose genotype can be reconstructed, 3) Families with ≥ 3 affected non-sibling family members, two of whom both alive and have living connecting relatives, and 4) Families with ≥ 3 affected, with one living and at least one other affected relative whose genotype can be reconstructed.**Methods:** The Coordinating Center is located at the University of Cincinnati (UC); with 26 study centers (40 sites) throughout the U.S., Canada, Australia and New Zealand. After obtaining an informed consent each subject is administered a questionnaire covering medical history, environmental risk factors, demographics and a blood sample is obtained. DNA extraction from blood is performed at UC. Immortalization of cell lines occurs at the Coriell Institute and becomes part of the NIH Stroke Repository. Identification of an undiagnosed IA is accomplished by magnetic resonance angiography (MRA) in subjects who are ≥ 30 years of age, who smoke or have hypertension. MRAs are reviewed at the Imaging Center at the Mayo Clinic. Performance of the genome screen is preformed at the Center for Inherited Disease Research (CIDR). As of August, 2005 the project changed for STRP to SNP genotyping. Nonparametric (allele sharing) linkage analysis, including environmental risk factors is conducted at Indiana University. Finally, fine gene mapping will be performed at UC.**Results:** During the first 31 months of enrollment (3/1/03-9/30/05) 585 probands have been identified and over 2300 individuals have been enrolled. The genome screen has been performed on 223 families. MRA screening has been completed on 257 individuals with 20% of individuals having an IA detected on MRA.**PI/Coordinator Name(s)[REQUIRED]:**UC:J. Broderick, D. Kleindorfer, D. Woo, M. Zuccarello, A. Ringer, K. Franklin, L. Sauerbeck; *UAL*:W. Fisher, H. Forson; *New Zealand*:C.Anderson, E. Mee, C. Howe, S. Vos; *Australia*:G. Hankey, P. DUrso, N. Knuckey, J. Laidlaw, P. Reilly, N. Dorsch, M. Morgan, M. Besser, PIs; K. Stewart, Claxton, J. Davidson, V. Dunne, J. Griffith, S. Pope; *Brigham's*:A. Day, PI, J. O'Hare; *Cleveland C*:P. Ramussen, D. Andrews-Hinders; *Columbia*:E.Connolly, R. Sacco, C. Naughton, C; *UFI*:S. Lewis, A. Royster; *ING*:T. Payner, N. Miracle; *London HSC*:G. Ferguson, C. Mayer, J. Peacock; *John Hopkins*:K. Murphy, B. Kohler; *Mass Gen*:C. Ogilvy, D. Buckley; *Notre Dame*:G. Rouleau, A. Noreau; *UMD*:E. Aldrich, C. Aldrich; *Mayo*:R. Brown, I. Meissner, D. Weibers, L. Jaeger; *UMI*:L. Lisabeth, K. Maddox; *NW*:H. Batjer, G. Joven, K. Matijevich; *U Ottawa*: M. Richard, A. Hopper; *U Pitts*:A. Kassam, K. Lee; *UCSF*:C. Johnston, K. Katsura; *USC*:S. Giannotta, V. Thomson, D. Fishback; *Stanford*: G. Steinberg, D. Luu; *UVA*: N. Kassel, B. Worrall, P. Casebolt; *UWA*:D. Tirschwell, P. Tanzi; *U Manitoba*:A. Kaufmann, D. Gladish; *Wash U*:C. Derdeyn, M. Catanzaro.**PI/Coordinator Affiliation(s) [REQUIRED]:** (see above)**Trial Sponsor(s) [REQUIRED]:** NINS**Trial Contact Information (name, e-mail, web, fax, and/or phone) [REQUIRED]:** Laura R. Sauerbeck, laura.sauerbeck@uc.edu; (800) 503-3427**Trial E-mail:****Trial Web Site:** www.med.uc.edu/neurology/fia/**Date:** Thursday, February 16, 2006**Session Info:** Ongoing Clinical Trials Poster Abstracts - Thursday, February 16, 2006, 5:30 PM - 7:30 PM**Room:** Florida Exhibit Hall F[Close Window](#)